Navigation Links
EpiVax receives JDRF program funding to develop diabetes drug using natural 'regulatory' T-cells
Date:10/25/2007

October 25, 2007 (Providence, RI)--- EpiVax, Inc, a leader in the field of computational immunology, announced today that it has received funding from the Juvenile Diabetes Research Foundation (JDRF), the worlds largest charitable funder of Type 1 diabetes research, to develop Epi-13, a novel therapeutic for the prevention and treatment of type I diabetes, a devastating and chronic autoimmune disease that affects up to three million Americans today.

JDRF will provide EpiVax $351,000 for one year to provide a first proof-of-principle for the drug that will focus on the natural regulatory T cells and their protective role in the diabetes patient. The studies are anticipated to show that the drug reduces harmful immune responses to insulin-producing cells, preserving the bodys ability to make its own insulin.

JDRFs research funding provides an exciting opportunity to accelerate the proof of concept and commercial development of an immune-based therapy for Type 1 diabetes, said Anne De Groot, M.D., President and CEO of EpiVax. We hope to make it possible for persons living with diabetes to reduce insulin dependence and to live longer with fewer symptoms.

As antigen specific tolerance continues to be a major goal area in Autoimmunity for JDRF, the proposal from EpiVax presents a novel approach that could potentially generate or restore immune regulation in type 1 diabetes, said Teodora Staeva-Vieira, Ph.D., Director of the Autoimmunity Program at JDRF.

JDRF funds diabetes research across a range of scientific areas, including autoimmunity, regeneration, islet cell replacement, complications, and metabolic control. The agreement with EpiVax is a part of JDRFs innovative Industry Discovery and Development Partnership program, through which JDRF partners with pharmaceutical, biotech, and medical device businesses who are looking to develop drugs, treatments, technologies, and other therapeutics leading to a cure, reversal, or prevention of type 1 diabetes and its complications.

In most patients with Type 1 diabetes, immune responses to the bodys insulin protein diminish insulin production; thus blood sugar is not properly regulated. The insulin protein can be produced in the laboratory and administered as therapy, but this requires frequent injections for life.

The approach used by EpiVax is called Antigen-Specific Adaptive Tolerance Induction (ASATI) to specifically target and reduce undesirable immune responses. EpiVax used its proprietary computer algorithms to identify the molecules that induce ASATI. Because ASATI uses the bodys own natural responses, this intervention has the potential to be far safer than immunosuppressive drugs that are now being studied. The promising treatment, called Epi-13, may have application to a broad range of auto-immune disorders.

EpiVax is pioneering the use of immunoinformatics for making safer, more effective human therapeutics. This approach also offers hope for individualizing therapies, also known as immuno-pharmacogenomics.

The EpiVax research program will be carried out in collaboration with Dr. David Scott of the University of Maryland and with Robert Smith of the Hallett Center for Diabetes and Endocrinology at Rhode Island Hospital. According to Dr. Smith, an expert in the treatment of Type 1 diabetes, This research deals with a critically important clinical problem and the approach EpiVax is taking in developing new diabetes therapies holds great promise.


'/>"/>

Contact: Susan Sherman
ssherman@jdrf.org
212-479-7510
Juvenile Diabetes Research Foundation International
Source:Eurekalert

Related medicine news :

1. Infant receives first bloodless liver transplant
2. British MPs Say Prostate Cancer Receives Low Priority in the NHS
3. Fifth US Patient Receives Artificial Heart
4. Northfield Labs Receives FDA Comments
5. Abbott Receives CE Mark Certification
6. Zactima Receives Fast Track Designation By The FDA
7. East London Receives World Class New Private Hospital Facility
8. Brinda Karat Receives Legal Notice over Ramdev Issue
9. Quake-Hit Pakistan Receives 30 Field Hospitals From Cuba
10. Medtronic’s Insulin Pump Receives Regulatory Approva
11. Aurobindo Receives Approval from USFDA for anti-AIDS drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... Maureen McLaughlin, LA.c., ... Reproductive Medicine Associates of Connecticut (RMACT). McLaughlin brings nearly 20 years of experience ... to help patients realize their family building goals. Acupuncture helps fertility patients ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Fred Rides a Train” allows readers to ... , “Fred Rides a Train” is the creation of published author, Janet Morrison, ... teen years in Michigan. The "Fred, the Dog" series is her first attempt at ...
(Date:12/7/2016)... ... December 07, 2016 , ... NuevaCare, a leading home care agency ... to announce new city-specific pages as part of its ambitious website relaunch. As Bay ... look, first, for local agencies serving their city. The new site has several key ...
(Date:12/6/2016)... ... December 06, 2016 , ... Men with gum ... risk of serious health problems, such as cardiovascular illness, according to research cited ... Beverly Hills Periodontics & Dental Implant Center notes that the correlation between periodontal ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... has named Ajdin Camaga as a vice president of sales. , “Ajdin understands ... president. “He works hard to understand what each client needs, and is persistent ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... Dec. 7, 2016  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ... present a company overview at the BMO Capital Markets Prescriptions for ... York, NY . A live webcast of the ... the Ionis website.  The replay will be available within 48 hours ... ...
(Date:12/7/2016)... 7, 2016 Today, Stock-Callers.com presents four ... JAZZ ), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH ... AveXis Inc. (NASDAQ: AVXS ). From its peak ... 37% to reach a level equal to what it saw ... approximately 14% for the year, it has still out-performed other ...
(Date:12/7/2016)... According to the latest market ... Study on Multiplex Detection Immunoassay: North America to Dominate ... detection immunoassay market is expected to witness a CAGR of ... ...      (Logo: http://photos.prnewswire.com/prnh/20161114/438683LOGO) ...
Breaking Medicine Technology: